Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1998 May 9;316(7142):1417-22.
doi: 10.1136/bmj.316.7142.1417.

Screening for human T cell leukaemia/lymphoma virus among blood donors in Sweden: cost effectiveness analysis

E Tynell  1 , S Andersson, E Lithander, M Arneborn, J Blomberg, H B Hansson, A Krook, M Nomberg, K Ramstedt, A Shanwell, A Bjorkman
Affiliations

Screening for human T cell leukaemia/lymphoma virus among blood donors in Sweden: cost effectiveness analysis

E Tynell et al. BMJ. .

Abstract

Objective: To analyse the cost effectiveness of a national programme to screen blood donors for infection with the human T cell leukaemia/lymphoma virus.

Design: Three models for calculating the costs and benefits of screening were developed. The first model analysed the cost of continuously testing all donations; the second analysed the cost of initially testing new blood donors and then retesting them after five years; the third analysed the cost of testing donors only at the time of their first donation. Patients who had received blood components from donors confirmed to be infected with the virus were offered testing.

Setting: Sweden.

Main outcome measures: Prevalence of infection with the virus among blood donors, the risk of transmission of the virus, screening costs, and the outcome of infection.

Results: 648 497 donations were tested for the virus; 1625 samples tested positive by enzyme linked immunosorbent assay. 6 were confirmed positive by western blotting. The prevalence of infection with the virus was 2/100 000 donors. 35 patients who had received blood infected with the virus were tested; 3 were positive. The cost of testing every donation was calculated to be $3.02m (1.88m pounds); this is 18 times higher than the cost of testing new donors only, and only 1 additional positive donor would be discovered in 7 years. Regardless of the model used, screening was estimated to prevent only 1 death every 200 years at a minimum cost of $36m (22.5m pounds).

Conclusion: Based on these estimates the Swedish National Board of Health and Welfare decided that only new blood donors would be screened for infection with the virus.

PubMed Disclaimer

References

    1. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell Iymphoma. Proc Natl Acad Sci U S A. 1980;77:7415–7419. - PMC - PubMed
    1. Kalyanaraman VS, Sarngadharan MG, Robert-Gurhoff M, Miyoshi I, Golde D, Gallo RC. A new subtype of human T-cell leukemia virus (HTLV II) associated with a T-cell variant of hairy cell leukemia. Science. 1982;218:571–573. - PubMed
    1. Anonymous Licensure of screening tests for antibody to human T-lymphotropic virus type-I. MMWR Morb Mortal Wkly Rep. 1988;37:736–740. , 745-7. - PubMed
    1. Osame M, Matsumoto M, Usuku K, Izumo S, Ijichi N, Amitani H, et al. Chronic progressive myelopathy associated with elevated antibodies to human T-lymphotropic virus type I and adult T-cell leukemia-like cells. Ann Neurol. 1987;21:117–122. - PubMed
    1. Yamaguchi K. Human T-lymphotropic virus type I in Japan. Lancet. 1994;343:213–216. - PubMed

MeSH terms